Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 4:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 3,407 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Bone Tumor Clear all
Completed Phase 2 Interventional Results available

Bone Marrow Transplantation of Patients in Remission Using Partially Matched Relative Donor

NCT01350245
View directory record Official record
Conditions
Acute Myeloid Leukemia, Myelodysplastic Syndromes, Biphenotypic Leukemia, Acute Lymphocytic Leukemia, Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Plasma Cell Neoplasms, Lymphoma, Hodgkin's Disease, Aplastic Anemia
Interventions
Total Body Irradiation (TBI), Donor Lymphocyte Infusion (DLI), Cyclophosphamide, Mycophenolate Mofetil (MMF), Tacrolimus, Hematopoietic stem cell transplantation (HSCT)
Radiation · Biological · Drug + 1 more
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 16, 2025 · Synced Oct 26, 2026, 4:53 AM EDT
Withdrawn Phase 1Phase 2 Interventional

Inotuzumab Ozogamicin and Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia

NCT03851081
View directory record Official record
Conditions
Allogeneic Hematopoietic Stem Cell Transplantation Recipient, Blasts 5 Percent or More of Bone Marrow Nucleated Cells, Blasts 5 Percent or More of Peripheral Blood White Cells, CD22 Positive, Lymphoblasts 20 Percent or More of Bone Marrow Nucleated Cells, Lymphoblasts 20 Percent or More of Peripheral Blood White Cells, Recurrent B Acute Lymphoblastic Leukemia, Refractory B Acute Lymphoblastic Leukemia
Interventions
Inotuzumab Ozogamicin, Quality-of-Life Assessment, Vincristine Sulfate Liposome
Biological · Other · Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jan 28, 2022 · Synced Oct 26, 2026, 4:53 AM EDT
Completed Phase 1 Interventional

Study of PXD101 Alone and in Combination With 5-Fluorouracil (5-FU) in Patients With Advanced Solid Tumors

NCT00413322
View directory record Official record
Conditions
Tumor
Interventions
belinostat, 5-Fluorouracil (5-FU)
Drug
Lead sponsor
Valerio Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
3
States / cities
Scottsdale, Arizona • Omaha, Nebraska • Portsmouth, New Hampshire
Source: ClinicalTrials.gov public record
Updated Jul 8, 2015 · Synced Oct 26, 2026, 4:53 AM EDT
Completed Phase 1 Interventional

Study of TCP-ATRA for Adult Patients With AML and MDS

NCT02273102
View directory record Official record
Conditions
Acute Myelogenous Leukemia, Myelodysplastic Syndromes, Leukemia
Interventions
Tranylcypromine, Tretinoin
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 21, 2020 · Synced Oct 26, 2026, 4:53 AM EDT
Completed Phase 1Phase 2 Interventional

Etanercept for Non-Infectious Lung Injury Following Bone Marrow Transplantation

NCT00029328
View directory record Official record
Conditions
Respiratory Distress Syndrome, Adult, Bronchiolitis Obliterans, Pneumonia
Interventions
etanercept
Drug
Lead sponsor
FDA Office of Orphan Products Development
Federal
Eligibility
12 Months and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 25, 2015 · Synced Oct 26, 2026, 4:53 AM EDT
Completed Not applicable Interventional Results available

Therapy of HES, PV, Atypical Chronic Myelocytic Leukemia (CML) or Chronic Myelomonocytic Leukemia (CMML), and Mastocytosis With Imatinib Mesylate

NCT00038675
View directory record Official record
Conditions
Chronic Myelomonocytic Leukemia, Chronic Myeloid Leukemia, Polycythemia Vera, Hypereosinophilic Syndrome, Mastocytosis
Interventions
Imatinib Mesylate (Gleevec)
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2013
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 4, 2022 · Synced Oct 26, 2026, 4:53 AM EDT
Terminated Phase 2 Interventional Results available

Donor Umbilical Cord Blood Natural Killer Cells, Aldesleukin and Umbilical Cord Blood Transplant in Patients With Refractory Hematologic Cancers.

NCT00354172
View directory record Official record
Conditions
Leukemia, Myelodysplastic Syndromes
Interventions
aldesleukin, filgrastim, natural killer cell (NK) therapy, cyclophosphamide, cyclosporine, fludarabine phosphate, methylprednisolone, mycophenolate mofetil, Umbilical Cord Blood Transplantation (UCBT), Total body irradiation (TBI)
Biological · Drug · Procedure + 1 more
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 45 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 28, 2017 · Synced Oct 26, 2026, 4:53 AM EDT
Completed Phase 1 Interventional

Total Body Irradiation With Fludarabine Followed by Combined Umbilical Cord Blood (UCB) Transplants

NCT00606437
View directory record Official record
Conditions
Lymphoma, Myeloma, Leukemia, Myelodysplasia, Solid Tumors, Hodgkin's Disease, Myelofibrosis
Interventions
Total Body Irradiation with Fludarabine in UCB Transplants
Procedure
Lead sponsor
Duke University
Other
Eligibility
14 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2014
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 16, 2014 · Synced Oct 26, 2026, 4:53 AM EDT
Recruiting Phase 2 Interventional

Eflornithine (DFMO) for Ewing Sarcoma and Osteosarcoma

NCT07321912
View directory record Official record
Conditions
Osteosarcoma, Ewing Sarcoma
Interventions
Eflornithine, Topotecan, Cyclophosphamide, Vincristine, Doxorubicin, Ifosfamide, Etoposide, Cisplatin, Methotrexate
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
0 Years to 50 Years
Enrollment
406 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2036
U.S. locations
3
States / cities
Tampa, Florida • Portland, Oregon • Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 26, 2026, 4:53 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Natural Killer Cells Before and After Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia

NCT01904136
View directory record Official record
Conditions
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia With Gene Mutations, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, de Novo Myelodysplastic Syndrome, Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Therapy-Related Acute Myeloid Leukemia
Interventions
Allogeneic Hematopoietic Stem Cell Transplantation, Bone Marrow Transplantation, Cyclophosphamide, Fludarabine, Laboratory Biomarker Analysis, Melphalan, Mycophenolate Mofetil, Natural Killer Cell Therapy, Peripheral Blood Stem Cell Transplantation, Tacrolimus, Total-Body Irradiation
Procedure · Drug · Other + 2 more
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
2 Years to 65 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 24, 2024 · Synced Oct 26, 2026, 4:53 AM EDT
Not listed No phase listed Observational

Pelvic Fractures and Radiation Therapy for Cervical Cancer

NCT00800644
View directory record Official record
Conditions
Cervical Cancer, Endometrial Cancer, Vaginal Cancer
Interventions
CT or MRI + Blood Test
Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Female only
Enrollment
239 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 13, 2020 · Synced Oct 26, 2026, 4:53 AM EDT
Active, not recruiting Phase 3 Interventional

Mismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for Children, Adolescents, and Young Adults With Acute Leukemia or Myelodysplastic Syndrome

NCT05457556
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Mixed Phenotype Acute Leukemia, Myelodysplastic Syndrome
Interventions
Biospecimen Collection, Bone Marrow Aspiration, Busulfan, Cyclophosphamide, Echocardiography Test, Fludarabine, Haploidentical Hematopoietic Cell Transplantation, Lapine T-Lymphocyte Immune Globulin, Lumbar Puncture, Matched Unrelated Donor Hematopoietic Cell Transplantation, Melphalan, Methotrexate, Multigated Acquisition Scan, Mycophenolate Mofetil, Myeloablative Conditioning, Quality-of-Life Assessment, Questionnaire Administration, Rituximab, T-Cell Depletion Therapy, Tacrolimus, Thiotepa, Total-Body Irradiation
Procedure · Drug · Biological + 2 more
Lead sponsor
Children's Oncology Group
Network
Eligibility
6 Months to 21 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
57
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 49 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 26, 2026, 4:53 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis)

NCT04817007
View directory record Official record
Conditions
Myelofibrosis
Interventions
BMS-986158, Ruxolitinib, Fedratinib
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
8
States / cities
Newport Beach, California • Lake Mary, Florida • New Orleans, Louisiana + 5 more
Source: ClinicalTrials.gov public record
Updated May 8, 2026 · Synced Oct 26, 2026, 4:53 AM EDT
Terminated Phase 2 Interventional Results available

Selinexor in Treating Patients With Abiraterone Acetate and/or Enzalutamide Refractory Metastatic Castration-Resistant Prostate Cancer

NCT02215161
View directory record Official record
Conditions
Castration Levels of Testosterone, Hormone-Resistant Prostate Cancer, Metastatic Prostate Carcinoma in the Soft Tissue, Prostate Carcinoma Metastatic in the Bone, PSA Progression, Stage IV Prostate Adenocarcinoma AJCC v7
Interventions
Selinexor
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older · Male only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 26, 2018 · Synced Oct 26, 2026, 4:53 AM EDT
Active, not recruiting Phase 1 Interventional

Study Transplanting Bone Marrow Cells Into Salivary Glands to Treat Dry Mouth Caused by Radiation Therapy

NCT05820711
View directory record Official record
Conditions
Head and Neck Cancer, Xerostomia
Interventions
MSC
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 90 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Oct 26, 2026, 4:53 AM EDT
Recruiting Phase 1 Interventional

Genetically Engineered Cells (FH-FOLR1 ST CAR T Cells) for the Treatment of Advanced Refractory or Recurrent/Progressive Osteosarcoma, FIERCe Trial

NCT07227571
View directory record Official record
Conditions
Advanced Osteosarcoma, Recurrent Osteosarcoma, Refractory Osteosarcoma
Interventions
FH FOLR1 ST CAR T-cells, Leukapheresis, Fludarabine, Cyclophosphamide, Echocardiography Test, Multigated Acquisition Scan, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography, Biopsy Procedure
Biological · Procedure · Drug
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
1 Year to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2044
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 26, 2026, 4:53 AM EDT
Completed Phase 2 Interventional

Fludarabine Phosphate, Busulfan, and Anti-Thymocyte Globulin Followed By Donor Peripheral Blood Stem Cell Transplant, Tacrolimus, and Methotrexate in Treating Patients With Myeloid Malignancies

NCT01056614
View directory record Official record
Conditions
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Blastic Phase Chronic Myelogenous Leukemia, Childhood Acute Myeloid Leukemia in Remission, Childhood Chronic Myelogenous Leukemia, Childhood Myelodysplastic Syndromes, Chronic Phase Chronic Myelogenous Leukemia, de Novo Myelodysplastic Syndromes, Hematopoietic/Lymphoid Cancer, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Previously Treated Myelodysplastic Syndromes, Recurrent Adult Acute Myeloid Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Relapsing Chronic Myelogenous Leukemia
Interventions
fludarabine phosphate, busulfan, anti-thymocyte globulin, tacrolimus, methotrexate, peripheral blood stem cell transplantation, allogeneic hematopoietic stem cell transplantation, laboratory biomarker analysis
Drug · Biological · Procedure + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Up to 60 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2016
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 6, 2016 · Synced Oct 26, 2026, 4:53 AM EDT
Completed Phase 1 Interventional

A Study of BBI608 in Adult Patients With Advanced, Refractory Hematologic Malignancies

NCT02352558
View directory record Official record
Conditions
Hematologic Malignancy
Interventions
BBI608, Dexamethasone, Bortezomib, Imatinib, Ibrutinib
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
8
States / cities
Denver, Colorado • Indianapolis, Indiana • Germantown, Tennessee + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2023 · Synced Oct 26, 2026, 4:53 AM EDT
Withdrawn Phase 1Phase 2 Interventional

A Study of Ruxolitinib in Combination With Nilotinib in Patients With Chronic Phase CML

NCT02973711
View directory record Official record
Conditions
Leukemia, Chronic Myeloid
Interventions
Nilotinib, Ruxolitinib
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
2
States / cities
Ann Arbor, Michigan • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 16, 2021 · Synced Oct 26, 2026, 4:53 AM EDT
Terminated Phase 2 Interventional

Combination Chemotherapy Before and After Surgery in Treating Patients With Osteosarcoma

NCT00019864
View directory record Official record
Conditions
Cardiac Toxicity, Sarcoma
Interventions
filgrastim, cisplatin, dexrazoxane hydrochloride, doxorubicin hydrochloride, leucovorin calcium, methotrexate, adjuvant therapy, conventional surgery, neoadjuvant therapy
Biological · Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 25 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2011
U.S. locations
4
States / cities
Bethesda, Maryland • Oklahoma City, Oklahoma • Fort Worth, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2015 · Synced Oct 26, 2026, 4:53 AM EDT
Completed Phase 2 Interventional Results available

Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia and High-risk Myelodysplastic Syndrome

NCT00968071
View directory record Official record
Conditions
Acute Myelogenous Leukemia, Myelodysplastic Syndrome
Interventions
Decitabine, Gemtuzumab Ozogamicin
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
16 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 8, 2013 · Synced Oct 26, 2026, 4:53 AM EDT
Completed Phase 1 Interventional

Study of Lenzilumab in Previously Treated Patients With Chronic Myelomonocytic Leukemia (CMML)

NCT02546284
View directory record Official record
Conditions
Chronic Myelomonocytic Leukemia (CMML)
Interventions
lenzilumab
Drug
Lead sponsor
Humanigen, Inc.
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
2
States / cities
Tampa, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 28, 2020 · Synced Oct 26, 2026, 4:53 AM EDT
Completed Phase 2 Interventional

Vaccine Therapy in Treating Patients With Chronic Myelogenous Leukemia

NCT00004052
View directory record Official record
Conditions
Leukemia
Interventions
QS21, bcr-abl peptide vaccine
Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
16 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2005
U.S. locations
2
States / cities
New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 25, 2013 · Synced Oct 26, 2026, 4:53 AM EDT
Completed Phase 2 Interventional

Chemotherapy Toxicity Reduction Via Urea Cycle Support

NCT00223730
View directory record Official record
Conditions
Cancer
Interventions
Citrulline, Placebo
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
13 Years to 65 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2007
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 26, 2026, 4:53 AM EDT